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The use of stent-grafts to manage thoracic aortic dis- “in-house” devices Dake demonstrated a 1 and 2 year
survival of 81 and 73% that probably equates to theease is now a reality but many issues need to be
addressed. This editorial presents the thoughts of the long-term results from surgery although good data to
substantiate this long-term comparison is missing.8authors with a view to stimulating debate amongst
the readers. Other data are generally low volume. Grabenwoger
treated 21 patients with a 100% technical success rate
and two deaths (9.5%).9 Won and colleagues managed
23 patients with aneurysmal disease.10 All 11 patients
Aneurysms with degenerative aneurysms were treated suc-
cessfully whereas there were two failures from 12The published 30-day mortality following surgical re- patients with chronic dissections. There were no deathspair of aneurysmal disease of the descending thoracic or paraplegia within 30 days and 91% survival at 1aorta is in the region of 2–21% with the majority of year. A series from Japan details 15 patients withunits reporting 5–15%.1–4 However a recent audit of chronic dissections who were successfully treatedcardiothoracic units in Great Britain and Ireland without death or paraplegia. No death or ruptureshowed a 34% mortality rate for procedures performed occurred out to an average follow-up of 24 months.11on bypass and 25% when performed without bypass.5 Whilst these data support the use of stent-grafts thereOther complications of thoracic surgery include para- are a number of problems. Firstly the volume of data
plegia or paraparesis in up to 5%, particularly where remains small with a lack of information on long-
surgery extends beyond the 8th intercostal space, renal term outcomes. Secondly, the relative costs of the two
failure in 5%, stroke in 3%, cardiac and pulmonary therapies is unknown. Thirdly, we are all aware of the
problems in 10% and 28% of patients.4,6 Postoperative structural failure of abdominal stent-grafts. The data
recovery is often protracted with time spent on an for thoracic work is smaller volume with shorter fol-
intensive care unit, and long-term rehabilitation may low-up. However one major provider of thoracic stent-
be considerable. Understandably the potential benefits grafts has already voluntarily removed their device
of a “minimally invasive” treatment utilising stent- from the market because of stent and spine fractures.
graft technology are attractive. Most data arises from In order for patients to appreciate the short-term gain
the U.S.A. The reported mortality rate is 0–9% with a from the stent-graft compared to surgery, the devices
paraplegia and stroke rate of less than 3%, and an must be robust enough to show longevity. Finally, in
incidence of renal insufficiency around 4% using com- order to provide Grade A recommendations the cur-
mercially available devices.7 The hospital stay has been rent guidelines require at least one randomised con-
reduced to an average of 3 days. Using first generation trolled trial.12 Herein lies the crux of the problem.
Given the marked disparity in 30 day outcomes be-
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Hospital, Sheffield S5 7AU, U.K. that would enable them to randomise patients betweenFootnote. Many of the issues presented here arise from a stimulating
meeting held recently at Guys Hospital, London. the two therapies. Without a randomised trial health
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policy makers may be reluctant to sanction the use of thrombosis of the false lumen was achieved in 74% of
cases, partial thrombosis in the rest and an associatedstent-grafts. This problem has recently been overcome
in the U.K. with the insight and understanding of the reduction in the size of aorta and false lumen over
time with no late deaths due to aortic rupture. CzermakSafety and Efficacy Register of New Interventional
Procedures of the Medical Royal Colleges (SERNIP). has also treated six of seven patients (seven acute, two
chronic) successfully.23 The perception of the differenceWhilst this group has recommended that thoracic
stent-grafts should only be placed as part of primary in outcomes between surgery and stent-graft therapy
for complicated type B dissection has lead to a numberresearch (category C) they have recently agreed that
submission of data to a National Thoracic Stent-Graft of approaches. Some clinicians now feel that stent-
grafts should be considered the treatment of choice.Registry fulfils this criteria. Hopefully other regulatory
authorities will follow suite. This largely ignores the small volume of available data
and lack of long-term outcome measures. Perhaps for
them submission of data to a large registry should be
mandatory. Others see the need for a randomised
Trauma controlled trial (RCT). Unfortunately no funded study
is currently available.
Traumatic thoracic aortic transections are an attractive Even more controversial is the use of stent-grafts to
situation in which to consider stent grafts. Only 14–18% manage uncomplicated acute type B dissections. The
of patients with this type of injury reach hospital number of patients not offered surgery or stent-graft
alive and approximately 15–39% will die during or who die late or require subsequent intervention for
following surgery. Approximately 2.3–28% of patients late dissection related events that may be remedied by
will develop paraplegia, the higher rate being as- stent-graft induced thrombosis of the false lumen (i.e.
sociated with the “clamp and sew” technique rather late rupture, aneurysm formation, progression of isch-
than the use of bypass or Gott Shunt.13 Excellent results aemia or dissection) is difficult to estimate from the
from endovascular repair have been reported, with literature but is probably approximately 12–30%.20,24,25
0–17% mortality and no paraplegia in four small It has been demonstrated that false lumen patency
series.14–17 Whilst these data are small, and the long- following dissection predicts both long term aneurysm
term integrity of stent-grafts in patients, some of whom formation and death,26 and that stent-grafts induce
will be young, is unknown, the potential for a min- false lumen thrombosis.22 If the supposition that false
imally invasive treatment to treat these extremely sick lumen thrombosis stops late events is correct then
patients seems clear. More widespread application of stent-grafts may be able to stop delayed rupture of
this technique will require the instant availability of the aorta following type B dissection. However with no
stent-grafts and the dissemination of this expertise to active intervention the false lumen will spontaneously
all major trauma centres. thrombose in 50% of patients 5 years following type
B dissection, and there are of course cost implications
to a therapy that may only benefit 12–30% of patients
in the long-term.26 Currently health purchasers are
Acute Dissection unlikely to agree to the treatment of uncomplicated
type B and a RCT is required.
The majority of acute type B dissections are now
managed medically with surgery being reserved for
complications (rupture, refractory hypertension, loc-
alised false aneurysms, continued pain or branch ves- Terminology
sel ischaemia) which results in a 30 day operative
mortality of 31–64%.18–21 If an abdominal operation is The assessment of the value of value of stent-grafts in
chronic dissections is confused by nomenclature. Torequired then there is an 80% operative mortality.18
Stent-grafts have been used primarily to manage acute many surgeons the clinical picture of chronic dissection
is a patient who presents with a thoracic aortic an-branch vessel ischaemia complicating type B dis-
section. The largest series from Stanford demonstrated eurysm where imaging demonstrates a dissection that
occurred many years ago. However chronicity is oftenrelief of ischaemia in 76% of cases; all cases of dynamic
obstruction and 40% of cases where the obstruction is used to describe a dissection of more than 2 weeks
old and, using this definition, two recent publicationthought to be a combination of dynamic and static
obstruction.22 The early 30-day mortality rate was only has advocated stent grafts for chronic dissection.11,27
Clearly there is a huge difference in the potential for16%. Of importance was the observation that complete
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